"Type 2 Diabetics with CVD • Phase 3 trial BETonMACE2 is planned with 5,000 - 6,000 patients with T2DM, recent ACS and low HDL levels"
Is the medical trial design parameters for BOM2 any different than BOM (1) except for the much larger patient trial?
Koo